

## Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference

LEXINGTON, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President & Chief Executive Officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference on Feb. 22, 2017 at 8:00 a.m. EST in New York City.

A corresponding webcast of the presentation can be accessed by visiting:

<http://www.veracast.com/webcasts/rbc/healthcare2017/76101119713.cfm>

The webcast will be archived shortly after the live event and will be available until May 24, 2017. It will also be available for 30 days on the Investor Relations section of the Curis website at [www.curis.com](http://www.curis.com).

### About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 that is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 and VISTA pathways, including PD-L1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD-1 and TIM-3 pathways, including PD-L1/TIM-3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge<sup>®</sup> for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis.

For more information, visit Curis's website at [www.curis.com](http://www.curis.com).

#### Contact:

James E. Dentzer  
Chief Financial Officer & Chief Administrative Officer  
Curis, Inc.  
617-503-6597  
[jdentzer@curis.com](mailto:jdentzer@curis.com)

#### Media Contact

David Schull  
Russo Partners  
(212) 845-4271  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

---

<https://investors.curis.com/Curis-to-Present-at-the-2017-RBC-Capital-Markets-Global-Healthcare-Conference>